Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum monitoring of anti-dementia drugs and its relevance to side effects, efficacy, and compliance
2017-002707-10Phase 4Completed
- Sponsor
- Regional Dementia Research Centre
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donepezil and memantine in Alzheimer's disease (AD), Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), sponsored by Regional Dementia Research Centre. Primary endpoint: Completion of 1-year follow-up for all patients. Started Nov 2017; status: completed.
02
Drugs
donepezilmemantine
03
Conditions
Alzheimer's disease (AD)Parkinson's disease dementia (PDD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on 2017-002707-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002707-10.